-
The Journal of Pediatrics Nov 1977Miconazole, a new imidazole antimycotic agent, was given intravenously to five children with chronic mucocutaneous candidiasis over an 18-month period. There was marked...
Miconazole, a new imidazole antimycotic agent, was given intravenously to five children with chronic mucocutaneous candidiasis over an 18-month period. There was marked improvement of mucosa and skin in two patients, moderate-to-milk improvement in two, and no improvement in one. Nail lesions were not improved in any patient. Adverse reactions included phlebitis, pruritus, nausea and dizziness, rash, wheezing, mild transient anemia, and mild transient transaminase (SGOT and SGPT) elevations; it was necessary to discontinue treatment in only one patient. No renal toxocity was noted. Miconazole appears to be a relatively safe and promising alternative to amphotericin B in chronic mucocutaneous candidiasis.
Topics: Adolescent; Candidiasis, Cutaneous; Child; Child, Preschool; Chronic Disease; Female; Humans; Imidazoles; Infant; Infusions, Parenteral; Male; Miconazole
PubMed: 909025
DOI: 10.1016/s0022-3476(77)81050-0 -
Pakistan Journal of Pharmaceutical... Jan 2024Hydrophilic drugs could be incorporated into the skin surface by manes of Lipogel. This study aimed to prepare miconazole lipogel with natural ingredients to enhance...
Hydrophilic drugs could be incorporated into the skin surface by manes of Lipogel. This study aimed to prepare miconazole lipogel with natural ingredients to enhance drug permeability using dimethyl Sulfoxide (DMSO). The miconazole lipogels, A1 (without DMSO) and A2 (with DMSO) were formulated and evaluated for organoleptic evaluation, pH, viscosity, stability studies, freeze-thawing, drug release profile and drug permeation enhancement. Results had stated that prepared lipogel's pH falls within the acceptable range required for topical delivery (4 to 6) while both formulations show good results in organoleptic evaluation. The A2 formulation containing DMSO shows better permeation of miconazole (84.76%) on the artificial skin membrane as compared to A1 lipogel formulation (50.64%). In in-vitro drug release studies, A2 for-mulation showed 87.48% drug release while A1 showed just 60.1% drug release from lipogel. Stability studies were performed on model formulations under environmental conditions and both showed good spreadibility, stable pH, free of grittiness and good consistency in formulation. The results concluded that A2 formulation containing DMSO shows better results as compared to DMSO-free drug lipogel.
Topics: Miconazole; Gels; Dimethyl Sulfoxide; Permeability; Drug Liberation; Viscosity; Drug Stability; Hydrogen-Ion Concentration; Skin Absorption; Chemistry, Pharmaceutical; Drug Compounding; Antifungal Agents; Administration, Cutaneous
PubMed: 38741405
DOI: No ID Found -
Journal of Clinical Pharmacy and... Dec 1987The sorption of the antifungal drug miconazole onto the plastics of infusion bags and intravenous administration sets has been investigated. HPLC methodology was applied...
The sorption of the antifungal drug miconazole onto the plastics of infusion bags and intravenous administration sets has been investigated. HPLC methodology was applied for the determination of miconazole concentrations. The results obtained indicate that the sorption of miconazole is low and is unlikely to result in significant loss of clinical efficacy.
Topics: Adsorption; Chromatography, High Pressure Liquid; Humans; Indicators and Reagents; Infusions, Intravenous; Ketoconazole; Miconazole
PubMed: 3440815
DOI: 10.1111/j.1365-2710.1987.tb00558.x -
Cutis Jan 1977In a well-controlled, double-blind, randomized study, 30 patients with cutaneous candidiasis were treated with a 2% miconazole nitrate lotion or its placebo control. By... (Clinical Trial)
Clinical Trial Randomized Controlled Trial
In a well-controlled, double-blind, randomized study, 30 patients with cutaneous candidiasis were treated with a 2% miconazole nitrate lotion or its placebo control. By the 14th day, 13 of the 15 patients [87%] treated with miconazole nitrate achieved clinical and mycologic cures. Only a single patient treated with the placebo lotion would be classified as a therapeutic cure. In a second portion of the study those patients judged to be therapeutic failures were treated with the lotion containing 2% miconazole nitrate. By combining the results of both portions of the study we find that miconazole nitrate lotion produced both a clinical and mycologic cure in all patients receiving the active lotion. The miconazole lotion formula was well tolerated by all patients and no side effects were noted. The fact that miconazole nitrate acts rapidly in relieving symptoms, is well tolerated, and is highly effective against dermatophytes, yeasts and gram-positive bacteria, makes it a welcome addition to available topical therapy of skin infections.
Topics: Candida albicans; Candidiasis, Cutaneous; Clinical Trials as Topic; Humans; Imidazoles; Intertrigo; Miconazole; Paronychia
PubMed: 319956
DOI: No ID Found -
Chemical & Pharmaceutical Bulletin 2019The purpose of this study was to prepare poly(lactide-co-glycolide) (PLGA) microspheres (MS) loaded with itraconazole (ITCZ) or miconazole (MCZ) under different...
The purpose of this study was to prepare poly(lactide-co-glycolide) (PLGA) microspheres (MS) loaded with itraconazole (ITCZ) or miconazole (MCZ) under different evaporation temperatures (25 or 40°C) using an oil-in-water emulsion solvent evaporation method in order to evaluate the initial burst release of drug. Loading efficiencies were comparatively good and the diameters of prepared drug-loaded PLGA MS were around 20 µm in all formulations. The release rates of ITCZ-PLGA MS prepared at 40°C showed a significantly restricted release profile compared with the corresponding ITCZ-PLGA MS prepared at 25°C. This difference in release rate of ITCZ was thought to be caused by the self-healing effect of PLGA, as the glass transition temperature of PLGA is around 40°C. With respect to the MCZ-PLGA MS, the initial burst release was similar in formulations prepared at both 25 and 40°C. Scanning electron microscope results suggested that the initial burst release was due to the localization of MCZ on the surface of MCZ-PLGA MS at higher concentrations. Differential scanning calorimetry measurements suggested complete amorphization of MCZ in MCZ-PLGA MS, whereas crystalline ITCZ was detected in the ITCZ-PLGA MS. This complete amorphization of MCZ is considered to be one of the reasons for the initial burst release.
Topics: Calorimetry, Differential Scanning; Drug Carriers; Drug Compounding; Itraconazole; Miconazole; Microspheres; Polyglactin 910
PubMed: 30713269
DOI: 10.1248/cpb.c18-00614 -
International Journal of Dermatology Sep 1990
Clinical Trial Comparative Study
Topics: Adolescent; Adult; Aged; Allylamine; Antifungal Agents; Arthrodermataceae; Child; Child, Preschool; Dermatomycoses; Female; Humans; Male; Miconazole; Middle Aged; Ointments
PubMed: 2228386
DOI: 10.1111/j.1365-4362.1990.tb04851.x -
The Journal of Infectious Diseases Dec 1983
Topics: Adult; Humans; Leishmaniasis; Male; Miconazole
PubMed: 6655297
DOI: 10.1093/infdis/148.6.1168 -
The Annals of Pharmacotherapy Feb 1999To describe three cases of interaction between miconazole oral gel and acenocoumarol, manifested as an increase in the international normalized ratio (INR).
OBJECTIVE
To describe three cases of interaction between miconazole oral gel and acenocoumarol, manifested as an increase in the international normalized ratio (INR).
CASE SUMMARIES
Three patients (62-year-old woman, 89-year-old woman, 43-year-old man) following oral antithrombotic treatment with acenocoumarol for different pathologies were diagnosed with oral candidiasis and started miconazole oral gel. In all cases, the previous INR values were repeatedly within the therapeutic range. The following routine monitoring of the antithrombotic therapy showed a marked increase in anticoagulant activity in all cases, which returned to the therapeutic range after miconazole was withdrawn. None of the patients needed substantial changes in their habitual dosages of acenocoumarol in subsequent measurements of the INR to stay within the therapeutic range.
DISCUSSION
We report three cases in which a possible interaction between miconazole oral gel and acenocoumarol is suggested by the chronological relationship between the introduction of miconazole and an increase in the INR. Miconazole exerts its fungistatic action by inhibiting some isoenzymes of the fungal cytochrome P450 system. Oral mucosa inflammation (as in oral candidiasis) may enhance its transmucosal absorption. In this setting, cytochrome P450 isoenzymes belonging to the host may be inhibited too. This mechanism provides an explanation for different interactions observed with miconazole oral gel.
CONCLUSIONS
Miconazole oral gel enhances acenocoumarol anticoagulant activity. Although we did not observe major bleeding complications, we suggest the use of other families of antifungal drugs, such as nystatin, to treat oral candidiasis in patients taking acenocoumarol.
Topics: Acenocoumarol; Administration, Oral; Adult; Aged; Aged, 80 and over; Anticoagulants; Antifungal Agents; Candidiasis, Oral; Drug Synergism; Female; Gels; Humans; International Normalized Ratio; Male; Miconazole; Middle Aged
PubMed: 10084413
DOI: 10.1345/aph.18011 -
European Journal of Obstetrics,... Mar 1980In a double-blind trial, 119 patients showing symptoms of Candida vulvovaginitis were treated with either 200 mg miconazole once daily for 6 days (A) or 400 mg... (Clinical Trial)
Clinical Trial Comparative Study
In a double-blind trial, 119 patients showing symptoms of Candida vulvovaginitis were treated with either 200 mg miconazole once daily for 6 days (A) or 400 mg miconazole once daily for 3 days (B), inserted intravaginally by means of a Scherer capsule. The efficacy was evaluated in 54 patients. A mycological cure rate was obtained in 93% of 29 patients from group A and in 80% of 25 patients from group B. The difference between the two therapy regimens was statistically not significant. No side-effects were observed.
Topics: Adult; Candidiasis; Drug Administration Schedule; Female; Humans; Imidazoles; Miconazole; Middle Aged; Time Factors; Vulvovaginitis
PubMed: 7189485
DOI: 10.1016/0028-2243(80)90061-1 -
The Journal of Antimicrobial... Oct 1986The serum concentrations of miconazole were measured in 11 healthy adult females for 72 hours following a single 1200 mg vaginal pessary. The mean peak serum miconazole...
The serum concentrations of miconazole were measured in 11 healthy adult females for 72 hours following a single 1200 mg vaginal pessary. The mean peak serum miconazole concentration was 10.4 micrograms/l and the mean elimination half life was 56.8 h. The mean area under the serum concentration time curve was 967 micrograms/l.h. The calculated mean systemic bioavailability of the vaginal pessary was 1.4%. There was large intersubject variation in serum miconazole pharmacokinetics. This formulation may provide effective single dose treatment for vaginal candidosis.
Topics: Absorption; Administration, Intravaginal; Adult; Female; Half-Life; Humans; Kinetics; Miconazole; Middle Aged; Vagina
PubMed: 3771433
DOI: 10.1093/jac/18.4.507